What is Immunovant Inc's share price today?
Immunovant Inc (IMVT) share price today is $30.51 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $30.58 and a day low of $28.18.What exchange does Immunovant Inc stock trade on, and under what ticker symbol?
Immunovant Inc stock trades on NASDAQ under the ticker symbol IMVT.What is Immunovant Inc's market capitalization?
Immunovant Inc's market capitalization is $6.17B as of November 7, 2026 at 2:29 AM IST.What is Immunovant Inc's price-to-earnings (P/E) ratio?
Immunovant Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.What is Immunovant Inc's price-to-book (P/B) ratio?
Immunovant Inc's price-to-book (P/B) ratio is 8.15 as of November 6, 2026.Can Indian investors buy Immunovant Inc shares?
Yes, You can buy Immunovant Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Immunovant Inc shares from India?
Indian investors can buy Immunovant Inc shares in three steps: 1. Search Immunovant Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Immunovant Inc shares for Indian investors?
Since Immunovant Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Immunovant Inc shares via Tickertape?
Indian investors can start investing in Immunovant Inc (IMVT) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3277 shares at the current price of $30.51.
$
₹
$30.517.48% (+2.12)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
8.15
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-2.82
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 17 analysts reports
Buy13 analysts
Hold4 analysts
Sell0 analyst
Price Upside
+60.09%
Earnings Growth
-10.5%
Rev. Growth
—
Company Profile
Company Profile
ABBV
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
MRNA
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$30.53Baseline
Analyst Target - 1 year
Target$48.88+60.09%
All values in $
2026
Current$30.53Baseline
Analyst Target - 1 year
Target$48.88+60.09%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2026
Current$-2.57Baseline
Forecast for Mar 2027
High$-2.52+2.04%
Average$-2.84-10.5%
Low$-3.05-18.73%
All values in $
2026
Current$-2.57Baseline
Forecast for Mar 2027
High$-2.52+2.04%
Average$-2.84-10.5%
Low$-3.05-18.73%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.5 | 0 | 0 | 0 | 0.16 | 0 | 0 | 0 | 0 | 7.09 |
| Gross Profit | 1.43 | -0.08 | -0.08 | -0.09 | 0.08 | -0.10 | -0.10 | -0.10 | - | 7.09 |
| Net Income | -75.31 | -87.15 | -109.11 | -111.12 | -106.44 | -120.61 | -126.50 | -110.63 | -147.85 | -153.22 |
| Net Profit Margin | -5021.26% | - | - | - | -66530.62% | - | - | - | - | -2159.60% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Immunovant Inc | - | 8.15 | - |
| AbbVie Inc | 50.65 | 50.45 | 0.58 |
| Amgen Inc | 27.73 | 21.33 | 2.75 |
Price Comparison
Price Comparison
Compare IMVT with any stock or ETFCompare IMVT with any stock or ETF
Comparing from
IMVT
ABBV
AMGN
The 12-month consensus target implies 60.09% growth, versus a trailing 3-year CAGR of -3.28%.